Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of
Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of directors.
Diatide is developing peptide-based imaging and therapy agentsthat are labeled with technetium-99m (SCAN 8/30/95). The firmplans to file a new drug application in 1997 for its lead product,an agent for the detection of deep vein thrombosis.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.